Wall Street analysts expect Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to announce earnings per share (EPS) of ($0.17) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.12). Conatus Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which suggests a positive year-over-year growth rate of 51.4%. The business is expected to issue its next quarterly earnings results on Wednesday, March 21st.
Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.08). The company had revenue of $9.57 million during the quarter, compared to the consensus estimate of $16.06 million. Conatus Pharmaceuticals had a negative net margin of 80.98% and a negative return on equity of 83.02%. During the same period in the prior year, the company earned ($0.31) earnings per share.
Several large investors have recently made changes to their positions in CNAT. State Street Corp acquired a new position in shares of Conatus Pharmaceuticals during the 2nd quarter worth approximately $2,092,000. Numeric Investors LLC acquired a new position in shares of Conatus Pharmaceuticals during the 2nd quarter worth approximately $1,620,000. Northern Trust Corp grew its position in shares of Conatus Pharmaceuticals by 640.6% during the 2nd quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock worth $1,712,000 after purchasing an additional 257,030 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Conatus Pharmaceuticals by 31.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock worth $5,800,000 after purchasing an additional 239,373 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Conatus Pharmaceuticals during the 2nd quarter worth approximately $1,041,000. Hedge funds and other institutional investors own 36.84% of the company’s stock.
Conatus Pharmaceuticals (NASDAQ CNAT) traded down $0.33 during trading on Tuesday, reaching $4.68. 596,800 shares of the company’s stock traded hands, compared to its average volume of 322,140. The company has a market cap of $140.43, a PE ratio of -5.78 and a beta of 1.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69. Conatus Pharmaceuticals has a 52-week low of $3.88 and a 52-week high of $9.40.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.